Roger von Moos

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

David H. Henry, Luís Costa, François Goldwasser et al. · Journal of Clinical Oncology · 2011 · 1.3K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

Jaafar Bennouna, Javier Sastre, Dirk Arnold et al. · The Lancet Oncology · 2012 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +10

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network

Caroline Voskens, Simone M. Goldinger, Carmen Loquai et al. · PLoS ONE · 2013 · 470 citations · Full text

Medicine, Oncology, Pharmacology +16

Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer

G. Fürstenberger, Roger von Moos, Rudolf Lucas et al. · British Journal of Cancer · 2006 · 206 citations · Full text

Medicine, Cancer Biology, Oncology +17

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

David H. Henry, Saroj Vadhan‐Raj, Vera Hirsh et al. · Supportive Care in Cancer · 2013 · 182 citations · Full text

Medicine, Oncology, Bone Metabolism +15